MEDIAN Technologies to take part in the annual 2014 Meeting of the RSNA in Chicago
MEDIAN Technologies (ALMDT), a leading medical imaging solution and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, will participate in the Annual Meeting of the Radiological Society of North America (RSNA), to be held next Nov. 30 – Dec. 5, in Chicago, USA.
MEDIAN Lesion Management Solutions (LMS) as well as MEDIAN imaging services for oncology patient management, clinical trials and lung cancer screening programs, will be presented in the MEDIAN booth #3442, French Pavilion, South Building, Hall A all along the conference.
The Annual Meeting of the Radiological Society of North America is the premier worldwide scientific and technical meeting of the medical imaging professional community. More than 60,000 professionals of the medical imaging will attend.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”